|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2006-7-25
|
|
pubmed:abstractText |
Angiotensin II receptor blockers (ARB) are now commonly used to treat hypertension because of their beneficial effects on cardiovascular remodeling. However, ARB treatment can not inhibit the left ventricular (LV) remodeling sufficiently, which may be related with aldosterone secretion. To inhibit the action of aldosterone during ARB treatment, the additional effects of an aldosterone blocker and spironolactone (SPRL) on LV hypertrophy in patients with essential hypertension was studied.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1346-9843
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
70
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
995-1000
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16864931-Aged,
pubmed-meshheading:16864931-Aldosterone,
pubmed-meshheading:16864931-Aldosterone Antagonists,
pubmed-meshheading:16864931-Angiotensin II,
pubmed-meshheading:16864931-Angiotensin II Type 1 Receptor Blockers,
pubmed-meshheading:16864931-Benzimidazoles,
pubmed-meshheading:16864931-Blood Pressure,
pubmed-meshheading:16864931-Echocardiography,
pubmed-meshheading:16864931-Female,
pubmed-meshheading:16864931-Heart Ventricles,
pubmed-meshheading:16864931-Hemodynamics,
pubmed-meshheading:16864931-Humans,
pubmed-meshheading:16864931-Hypertension,
pubmed-meshheading:16864931-Hypertrophy, Left Ventricular,
pubmed-meshheading:16864931-Male,
pubmed-meshheading:16864931-Middle Aged,
pubmed-meshheading:16864931-Natriuretic Peptide, Brain,
pubmed-meshheading:16864931-Spironolactone,
pubmed-meshheading:16864931-Tetrazoles,
pubmed-meshheading:16864931-Ventricular Remodeling
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy.
|
|
pubmed:affiliation |
Division of Cardiology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan. tani-guchi@jikei.ac.jp
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial
|
